Table 1.
Patient and tumor characteristics for all eligible patients.
| Totala | Non-participantsb | Participantsc | p | Study groupd | pe | ||
|---|---|---|---|---|---|---|---|
| n = 62 | n = 31 | n = 31 | n = 20 | ||||
| Men | 42 (68%) | 18 (58%) | 24 (77%) | NS | 15 (75%) | NS | |
| Age (median) (range, years) | 63 (39–78) | 64 (39–78) | 62 (46–73) | NS | 62 (46–73) | NS | |
| Smoking after RT | 10 (16%) | 9 (29%) | 1 (3%) | 0.01 | 0 | NS | |
| Follow-up after RT | |||||||
| 2–5 months | 34 (55%) | 18 (58%) | 16 (52%) | NS | 10 (50%) | NS | |
| 6–9 months | 13 (21%) | 7 (23%) | 6 (19%) | 5 (25%) | |||
| 10–12 months | 14 (23%) | 7 (23%) | 7 (23%) | 5 (25%) | |||
| >12 months | 1 (2%) | 1 (3%) | |||||
| Site | |||||||
| Pharynx | 48 (77%) | 25 (81%) | 23 (79%) | NS | 15 (75%) | NS | |
| Oral cavity | 10 (16%) | 5 (16%) | 5 (16%) | 3 (15%) | |||
| Saliva gland | 1 (2%) | 1 (3%) | - | ||||
| Unknown primary tumor | 3 (5%) | 1 (3%) | 2 (7%) | 2 (10%) | |||
| Clinical stage III–IV | 51 (82%) | 27 (87%) | 24 (77%) | NS | 16 (80%) | NS | |
| Concomitant chemotherapy | 32 (52%) | 13 (31%) | 19 (61%) | NS | 10 (50%) | 0.05 | |
| Distance to hospital | |||||||
| >50 km | 24 (39%) | 12 (36%) | 12 (41%) | NS | 10 (50%) | NS | |
| <50 km | 38 (61%) | 20 (65%) | 18 (58%) | 10 (50%) | |||
aTotal number of consecutive and eligible patients asked to participated in the study.
bNumber of patients declining to participate including screening failure.
cNumber of patients consenting to participate including patients not completing Visit 2.
dNumber of patients with repeating measurements who complete the study.
ep-Value comparing the patients completing the study with the patients lost to follow up.
RT, radiotherapy; NS, no significant p-value.